RESUMO
Objetive: To assess the frecuency and clinical picture of Hepatoportal Sclerosis in a population of Mexican children of the Instituto Nacional de Pediatría, México City. Background: Hepatoportal Sclerosis is a disease of unknown etiology. It's diagnosis is difficut. The main clinical presentation is splenomegaly with or without hematemesis (portal hypertension). Splenoportography and liver histology study are the best procedures for diagnosis and must be performed by experts. Methods: We studied 7/106 children with portal hypertension during a period of 10 years, who were seen at the Instituto Nacional de Pediatría, México city. Inclusion criteria were specifical findings of splenoportography and histologic changes in liver biopsy. Results: We found 7/106 children. The main clinical manifestation were splenomegaly and hematemesis. We did not find any previous history of contact with arsenisc, vinyl chloride or copper sulfate. In 6/7 children a porto-systemic shunt was performed. Only one received propranolol and sclerotheraphy. At the time of this report all children have shown a good clinical course.
Assuntos
Criança , Feminino , Humanos , Adolescente , Sistema Porta/patologia , Incidência , México/epidemiologia , Portografia , Estudos Retrospectivos , Esclerose/diagnóstico , Esclerose/epidemiologiaRESUMO
Objetive: To assess the frecuency and clinical picture of Hepatoportal Sclerosis in a population of Mexican children of the Instituto Nacional de Pediatría, México City. Background: Hepatoportal Sclerosis is a disease of unknown etiology. Its diagnosis is difficut. The main clinical presentation is splenomegaly with or without hematemesis (portal hypertension). Splenoportography and liver histology study are the best procedures for diagnosis and must be performed by experts. Methods: We studied 7/106 children with portal hypertension during a period of 10 years, who were seen at the Instituto Nacional de Pediatría, México city. Inclusion criteria were specifical findings of splenoportography and histologic changes in liver biopsy. Results: We found 7/106 children. The main clinical manifestation were splenomegaly and hematemesis. We did not find any previous history of contact with arsenisc, vinyl chloride or copper sulfate. In 6/7 children a porto-systemic shunt was performed. Only one received propranolol and sclerotheraphy. At the time of this report all children have shown a good clinical course. (AU)
Assuntos
Criança , Feminino , Humanos , Adolescente , Sistema Porta/patologia , Estudos Retrospectivos , Incidência , México/epidemiologia , Esclerose/diagnóstico , Esclerose/epidemiologia , PortografiaRESUMO
OBJECTIVE: To assess the frequency and clinical picture of Hepatoportal Sclerosis in a population of Mexican children of the Instituto Nacional de Pediatría, México City. BACKGROUND: Hepatoportal Sclerosis is a disease of unknown etiology. It's diagnosis is difficult. The main clinical presentation is splenomegaly with or without hematemesis (portal hypertension). Splenoportography and liver histology study are the best procedures for diagnosis and must be performed by experts. METHODS: We studied 7/106 children with portal hypertension during a period of 10 years, who were seen at the Instituto Nacional de Pediatría, México city. Inclusion criteria were specific findings of splenoportography and histologic changes in liver biopsy. RESULTS: We found 7/106 children. The main clinical manifestation were splenomegaly and hematemesis. We did not find any previous history of contact with arsenic, vinyl chloride or copper sulfate. In 6/7 children a porto-systemic shunt was performed. Only one received propranolol and sclerotherapy. At the time of this report all children have shown a good clinical course.
Assuntos
Sistema Porta/patologia , Adolescente , Criança , Feminino , Humanos , Incidência , Masculino , Portografia , Estudos Retrospectivos , Esclerose/diagnóstico , Esclerose/epidemiologiaRESUMO
Antecedentes. Diversos esquemas de tratamiento se han utilizado para la eliminación de Helicobacter pylori en niños con gastritis, con diferentes resultados. Objetivo. Evaluar la eliminación de Helicobacter pylori, así como la mejoría clínica en niños con gastritis asociada, cuando se les administró en forma simultánea amoxicilina, ranitidina y subsalicilato de bismuto. Método. Se estudiaron 20 pacientes que acudieron al Servicio de Gastroenterología, del Instituto Nacional de Pediatría, durante el periodo comprendido entre enero de 1992 y junio de 1993. Se incluyeron todos los niños con dolor abdominal recurrene en quienes se identificó Helicobacter pylori en las biopsias de antrogástrico. El tratamiento consistió en la administración simultánea de amoxicilina durante 15 días y ranitidina y subsalicilato de bismuto durante un mes. Resultados. En 14 de 20 niños se logró mejoría clínica así como la eliminación de Helicobacter pylori. Conclusiones. La eliminación de Helicobacter pylori y la mejoría clínica se obtuvieron en el 70 por ciento de los niños, con buena tolerancia al trataiento.
Assuntos
Humanos , Masculino , Feminino , Dor Abdominal/etiologia , Dor Abdominal/terapia , Biópsia , Tratamento Farmacológico , Úlcera Duodenal , Endoscopia , Gastrite , Helicobacter pyloriRESUMO
BACKGROUND: Different antibiotics, antagonist H2 and others have been used for elimination and/or eradication of Helicobacter pylori. AIMS: Evaluate elimination of Helicobacter pylori with amoxicillin, bismuth subsalicylate and ranitidine; and the improvement of recurrent abdominal pain. METHOD: 20 children with recurrent abdominal pain associated to gastritis and histologic identification of Helicobacter pylori were studied under a period of 18 months (January 1992 to June 1993), at Instituto Nacional de Pediatría, México, D.F. All children were treated simultaneously with: Amoxicillin, 15 days, plus ranitidine and bismuth subsalicylate for one month. RESULTS: Helicobacter pylori was eliminated in 14 of 20 children studied. All these children had an important improvement of recurrent abdominal pain. CONCLUSION: Elimination of Helicobacter pylori and clinical improvement was present in 14 of 20 children studied (70%).
Assuntos
Dor Abdominal/tratamento farmacológico , Amoxicilina/administração & dosagem , Antiulcerosos/administração & dosagem , Bismuto/administração & dosagem , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/efeitos dos fármacos , Compostos Organometálicos/administração & dosagem , Penicilinas/administração & dosagem , Ranitidina/administração & dosagem , Salicilatos/administração & dosagem , Amoxicilina/farmacologia , Antiulcerosos/farmacologia , Bismuto/farmacologia , Criança , Feminino , Humanos , Estudos Longitudinais , Masculino , Compostos Organometálicos/farmacologia , Penicilinas/farmacologia , Estudos Prospectivos , Ranitidina/farmacologia , Recidiva , Salicilatos/farmacologiaRESUMO
OBJECTIVE: Elimination of Helicobacter pylori with Chlaritromicin, Bismuth subsalicylate and Ranitidine; and improvement of recurrent abdominal pain. ANTECEDENT: Different antibiotics, antagonist H2 and others has been used for elimination and, or eradication of Helicobacter pylori. METHOD: 22 children with recurrent abdominal pain associated to gastritis and histologic identification of Helicobacter pylori were studied under a period of 18 months (january 1992 to june 1993), at Instituto Nacional de Pediatría, México, D:F: All children were treated simultaneously with: Chlaritromicin, 15 days, Plus ranitidine and bismuth subsalicylate for one month. RESULTS: Helicobacter pylori was eliminate in 14 of 22 children studied. All these children had an important improvement of recurrent abdominal pain. CONCLUSION: Elimination of Helicobacter pylori and clinical improvement was present in 14 of 22 children studied (63.7%).
Assuntos
Dor Abdominal/microbiologia , Antiulcerosos/farmacologia , Bismuto/farmacologia , Claritromicina/farmacologia , Gastrite/tratamento farmacológico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/efeitos dos fármacos , Antagonistas dos Receptores H2 da Histamina/farmacologia , Ranitidina/farmacologia , Antiulcerosos/uso terapêutico , Bismuto/uso terapêutico , Criança , Claritromicina/uso terapêutico , Quimioterapia Combinada , Feminino , Gastrite/microbiologia , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Humanos , Estudos Longitudinais , Masculino , Estudos Prospectivos , Ranitidina/uso terapêutico , RecidivaRESUMO
Objetivo: Evaluar la eliminación de Helicobacter pylori, así como la mejoría clínica en niños con gastritis asociada; cuando se les administró en forma simult nea claritromicina, ranitidina y subsalicilato de bismuto. Antecedentes: Diversos esquemas de tratamiento se han utilizado para la eliminación de Helicobacter pylori en niños con gastritis, con diferentes resultados. Método: Se estudiaron 22 pacientes que acudieron al servicio de Gastroenterología, del Instituto Nacional de Pediatría, durante el período comprendido entre enero de 1992 y junio de 1993. Se incluyeron todos los niños con dolor abdominal recurrente en quienes se identificó Helicobacter pylori en las biopsias de antro g strico. El tratamiento consistió en la administración simult nea de claritromicina durante 15 días y ranitidina y subsalicilato de bismuto durante un mes. Resultados: en 14 de 22 niños se logró mejoría clínica, así como la eliminación de Helicobacter pylori. Conclusiones: La eliminación de Helicobacter pylori y la mejoría clínica se obtuvieron en el 63.7 por ciento de los niños, con buena tolerancia al tratamiento.
Assuntos
Feminino , Humanos , Criança , Dor Abdominal/microbiologia , Antiulcerosos/farmacologia , Bismuto/farmacologia , Claritromicina/farmacologia , Gastrite/tratamento farmacológico , Helicobacter pylori/efeitos dos fármacos , Antagonistas dos Receptores H2 da Histamina/farmacologia , Ranitidina/farmacologia , Bismuto/uso terapêutico , Claritromicina/uso terapêutico , Quimioterapia Combinada , Gastrite/microbiologia , Infecções por Helicobacter/complicações , Estudos Longitudinais , Estudos Prospectivos , Ranitidina/uso terapêutico , Recidiva , Resultado do TratamentoRESUMO
Objetivo: Evaluar la eliminación de Helicobacter pylori, así como la mejoría clínica en niños con gastritis asociada; cuando se les administró en forma simult nea claritromicina, ranitidina y subsalicilato de bismuto. Antecedentes: Diversos esquemas de tratamiento se han utilizado para la eliminación de Helicobacter pylori en niños con gastritis, con diferentes resultados. Método: Se estudiaron 22 pacientes que acudieron al servicio de Gastroenterología, del Instituto Nacional de Pediatría, durante el período comprendido entre enero de 1992 y junio de 1993. Se incluyeron todos los niños con dolor abdominal recurrente en quienes se identificó Helicobacter pylori en las biopsias de antro g strico. El tratamiento consistió en la administración simult nea de claritromicina durante 15 días y ranitidina y subsalicilato de bismuto durante un mes. Resultados: en 14 de 22 niños se logró mejoría clínica, así como la eliminación de Helicobacter pylori. Conclusiones: La eliminación de Helicobacter pylori y la mejoría clínica se obtuvieron en el 63.7 por ciento de los niños, con buena tolerancia al tratamiento. (AU)